{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:13:29Z","timestamp":1792181609321,"version":"4.4.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic Rhinosinusitis with nasal polyps (CRSwNP) is a common chronic disease with a high impact on patients\u2019 quality of life. If conservative and surgical guideline treatment cannot sufficiently control disease burden, biologicals can be considered as a comparably new treatment option that has revolutionized CRSwNP therapy since the first approval of Dupilumab in 2019. With the aim to select patients who benefit from this new treatment and to find a marker for therapy monitoring, we investigated the cellular composition of nasal mucous membranes and inflammatory cells of patients suffering from CRSwNP and undergoing Dupilumab therapy using non-invasive nasal swab cytology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty CRSwNP patients with the indication for Dupilumab therapy have been included in this prospective clinical study. In total, five study visits were conducted with ambulatory nasal differential cytology using nasal swabs starting with the beginning of therapy and followed by visits every 3 months for 12 months. First, these cytology samples were stained with the May-Grunwald-Giemsa method (MGG) and the percentage of ciliated cells, mucinous cells, eosinophil cells, neutrophil cells, and lymphocytes was analyzed. Secondly, an immunocytochemical (ICC) ECP-staining was performed to detect eosinophil granulocytes. Additionally, during each study visit the nasal polyp score, SNOT20 questionnaire, olfactometry, the total IgE concentration in peripheral blood as well as the eosinophil cell count in peripheral blood were recorded. The change of parameters was evaluated over one year and the correlation between clinical effectiveness and nasal differential cytology was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In both MGG (p&amp;lt;0.0001) and ICC analysis (p&amp;lt;0.001) a significant decrease of eosinophils was seen under Dupilumab treatment. When patients were divided into a Eo-low- (&amp;lt;21%) and Eo-high- (\u226521%) group according to the percentage eosinophils in nasal swab catology in the first study visit, the Eo-high-group showed a greater change of eosinophils over time (\u039417.82) compared to the Eo-low-group (\u039410.67) but, however, no better response to therapy. The polyp score, SNOT20 questionnaire, and total IgE concentration in peripheral blood showed a significant decrease during the observation period (p&amp;lt;0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Nasal swab cytology as an easy-to-apply diagnostic method allows detection and quantification of the different cell populations within the nasal mucosa at a given time. The nasal differential cytology showed a significant decrease of eosinophils during Dupilumab therapy and can therefore be used as non-invasvive method for monitoring therapy success of this cost intensive therapy and potentially can allow an optimized individual therapy planning and management for CRSwNP patients. Since the validity of initial nasal swab eosinophil cell count as a predictive biomarker for therapy response was limited in our study, additional studies including larger number of participants will be necessary to further evaluate the potential benefits for clinical practice of this new diagnostic method.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1127576","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:19:47Z","timestamp":1681777187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Differential nasal swab cytology represents a valuable tool for therapy monitoring but not prediction of therapy response in chronic rhinosinusitis with nasal polyps treated with Dupilumab"],"prefix":"10.3389","volume":"14","author":[{"given":"Zeynep","family":"Danisman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Linxweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Linxweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich-Franz","family":"Solomayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Wagenpfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Berndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s40629-017-0048-5","article-title":"Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities","volume":"27","author":"Koennecke","year":"2018","journal-title":"Allergo J Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995","article-title":"Chronic rhinosinusitis in Europe\u2013an underestimated disease. a GA(2)LEN study","volume":"66","author":"Hastan","year":"2011","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.130.3.320","article-title":"Prevalence of the chronic sinusitis diagnosis in Olmsted county, Minnesota","volume":"130","author":"Shashy","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v2.i12.873","article-title":"Eosinophilic chronic rhinosinusitis in East asians","volume":"2","author":"Wang","year":"2014","journal-title":"World J Clin Cases"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin19.158","article-title":"The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0194-59989570152-4","article-title":"The health impact of chronic sinusitis in patients seeking otolaryngologic care","volume":"113","author":"Gliklich","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4193\/Rhin20.601","article-title":"Executive summary of EPOS 2020 including integrated care pathways","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin19.468","article-title":"Direct and indirect costs of adult patients with chronic rhinosinusitis with nasal polyps","volume":"58","author":"Lourijsen","year":"2020","journal-title":"Rhinology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/lary.25180","article-title":"Cost of adult chronic rhinosinusitis: A systematic review","volume":"125","author":"Smith","year":"2015","journal-title":"Laryngoscope"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.09.009","article-title":"Chronic rhinosinusitis in Asia","volume":"140","author":"Zhang","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2500\/ajr.2008.22.3228","article-title":"Perspectives on the etiology of chronic rhinosinusitis: an immune barrier hypothesis","volume":"22","author":"Kern","year":"2008","journal-title":"Am J Rhinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cea.12462","article-title":"Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia","volume":"45","author":"Ho","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.010","article-title":"Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases","volume":"139","author":"Schleimer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2013.27.3926","article-title":"Chapter 6: Nasal polyps","author":"Settipane","year":"2013","journal-title":"Am J Rhinol Allergy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-022-07634-x","article-title":"Comparison of guidelines for prescription and follow-up of biologics for chronic rhinosinusitis with nasal polyps","volume":"280","author":"Rampi","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1815683","article-title":"Systematic literature review of humanistic and economic burdens of chronic rhinosinusitis with nasal polyposis","volume":"36","author":"Chen","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.04.004","article-title":"Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps","volume":"129","author":"Borish","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: First global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22944","article-title":"Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps","volume":"12","author":"Hellings","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S243053","article-title":"Dupilumab: Clinical efficacy of blocking IL-4\/IL-13 signalling in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Kariyawasam","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0194599820939964","article-title":"Role of biologics in chronic rhinosinusitis with nasal polyposis: State of the art review","volume":"164","author":"Kim","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221105749","article-title":"Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps","volume":"38","author":"Koski","year":"2022","journal-title":"J Pharm Technol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13601-017-0157-8","article-title":"Endotype-driven treatment in chronic upper airway diseases","volume":"7","author":"De Greve","year":"2017","journal-title":"Clin Transl Allergy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12070-018-1468-3","article-title":"Study the role of nasal scrap cytology in allergic rhinitis patients in rural population","volume":"71","author":"Singhvi","year":"2019","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.09.005","article-title":"Rhinosinusitis: developing guidance for clinical trials","volume":"118","author":"Meltzer","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00106-005-1347-6","article-title":"[Quality of life in patients with chronic rhinosinusitis: validation of the sino-nasal outcome test-20 German adapted version]","volume":"55","author":"Baumann","year":"2007","journal-title":"HNO"},{"key":"B36","first-page":"37","article-title":"Nasal cytology","volume":"32","author":"Gelardi","year":"2018","journal-title":"J Biol Regul Homeost Agents"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2007.00634.x","article-title":"Cytology in the diagnosis of rhinosinusitis","author":"Gelardi","year":"2007","journal-title":"Pediatr Allergy Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.14639\/0392-100X-N0711","article-title":"Exploring the role of nasal cytology in chronic rhinosinusitis","volume":"40","author":"Gallo","year":"2020","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2014.12.006","article-title":"Immunopathology of chronic rhinosinusitis","volume":"64","author":"Kato","year":"2015","journal-title":"Allergol Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.05.041","article-title":"Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania","volume":"138","author":"Wang","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"14492","DOI":"10.1038\/s41598-022-18734-3","article-title":"Scraping nasal cytology in the diagnostics of rhinitis and the comorbidities","volume":"12","author":"Myszkowska","year":"2022","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"102286","DOI":"10.1016\/j.amjoto.2019.102286","article-title":"Predictive markers of long-term recurrence in chronic rhinosinusitis with nasal polyps","volume":"41","author":"Rosati","year":"2020","journal-title":"Am J Otolaryngol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1167\/tvst.9.3.29","article-title":"Dupilumab-associated mucin deficiency (DAMD)","volume":"9","author":"Barnett","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)91995-9","article-title":"Non-invasive sampling of nasal cilia for measurement of beat frequency and study of ultrastructure","volume":"2","author":"Rutland","year":"1980","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.14639\/0392-100X-1417","article-title":"Non-surgical management of chronic rhinosinusitis with nasal polyps based on clinical-cytological grading: a precision medicine-based approach","volume":"37","author":"Gelardi","year":"2017","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13207","article-title":"Nasal cytology: Methodology with application to clinical practice and research","volume":"48","author":"Heffler","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12730","article-title":"NASAL cytology: practical aspects and clinical relevance","volume":"46","author":"Gelardi","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2018.11.010","article-title":"Nasal cytology with deep learning techniques","volume":"122","author":"Dimauro","year":"2019","journal-title":"Int J Med Inform"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1127576\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T06:44:28Z","timestamp":1682577868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1127576\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2023.1127576"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1127576","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"article-number":"1127576"}}